Trial · NCT00595127
Hematopoietic Stem Cell Transplantation for Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using Total Body Irradiation, Cyclophosphamide and Fludarabine
NCT00595127, Not applicable, Completed, Memorial Sloan Kettering Cancer Center; results first posted 2016-08-10
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Hematopoietic Stem Cell Transplantation for Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using Total Body Irradiation, Cyclophosphamide and Fludarabine. Trials, record NCT00595127. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00595127
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Hematopoietic Stem Cell Transplantation for Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using Total Body Irradiation, Cyclophosphamide and Fludarabine
- NCT number
- NCT00595127
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 21 participants, actual
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Conditions
- Fanconi Anemia
- Interventions
- Cyclophosphamide, Fludarabine, Total body irradiation (TBI)
- First posted
- 2008-01-16
- Last updated
- 2016-08-10
- Results first posted
- 2016-08-10
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence & Quality of Engraftment & Hematopoietic Reconstitution | 8 years | Number of patients who engrafted |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Incidence & Quality of Engraftment & Hematopoietic Reconstitution | 8 years | participants | NUMBER |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Incidence & Quality of Engraftment & Hematopoietic Reconstitution | Cyclophosphamide and Fludarabine | 19 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Cyclophosphamide and Fludarabine | 21 | |
| Overall Study | COMPLETED | Cyclophosphamide and Fludarabine | 11 | |
| Overall Study | NOT COMPLETED | Cyclophosphamide and Fludarabine | 10 |
Source ClinicalTrials.gov
Adverse events25
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Alkaline phosphatase | Metabolism and nutrition disorders | Cyclophosphamide and Fludarabine | 3 | 21 | |
| other | Bilirubin | Blood and lymphatic system disorders | Cyclophosphamide and Fludarabine | 10 | 21 | |
| other | Hemoglobin (Hgb) | Metabolism and nutrition disorders | Cyclophosphamide and Fludarabine | 21 | 21 | |
| other | Hyperglycemia | Metabolism and nutrition disorders | Cyclophosphamide and Fludarabine | 15 | 21 | |
| other | Hyperkalemia | Metabolism and nutrition disorders | Cyclophosphamide and Fludarabine | 4 | 21 | |
| other | Hypermagnesmia | Metabolism and nutrition disorders | Cyclophosphamide and Fludarabine | 2 | 21 | |
| other | Hypertriglyceridemia | Metabolism and nutrition disorders | Cyclophosphamide and Fludarabine | 2 | 21 | |
| other | Hypocalcemia | Metabolism and nutrition disorders | Cyclophosphamide and Fludarabine | 2 | 21 | |
| other | Hypokalemia | Metabolism and nutrition disorders | Cyclophosphamide and Fludarabine | 14 | 21 | |
| other | Hyponatremia | Metabolism and nutrition disorders | Cyclophosphamide and Fludarabine | 8 | 21 |
1 to 10 of 25Source ClinicalTrials.gov
See all 25 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Cyclophosphamide and Fludarabine | ||
| Total, other adverse events | Cyclophosphamide and Fludarabine | 21 | 21 |
| Total, serious adverse events | Cyclophosphamide and Fludarabine | 5 | 21 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00595127
GET https://conductscience.org/api/trials/v1/NCT00595127/events?page=2